阿片类药物药物基因组学综述及疼痛管理考量
本文综述阿片类镇痛药的药物基因组学证据,重点讨论代谢酶基因多态性(尤其CYP2D6)对可待因和曲马多活化及不良反应的影响,以及OPRM1和COMT多态性与疗效的关联。CPIC已发布CYP2D6指导可待因和曲马多的治疗推荐,但其他常用阿片类药物尚缺乏实施指南。
要点
- CYP2D6多态性影响可待因和曲马多的生物活化,CPIC已据此给出治疗推荐。
- 代谢酶基因多态性可致阿片类药物暴露量差异,并可能影响恶心、呕吐、便秘和呼吸抑制的发生率。
- OPRM1和COMT多态性与阿片疗效的关联研究结果尚不一致,需进一步验证。
核心结论
- CYP2D6基因多态性可显著影响可待因和曲马多的药物暴露与代谢,CPIC据此提供个体化治疗推荐。
- OPRM1和COMT多态性与阿片类药物疗效的关联证据尚不一致,部分研究提示OPRM1可能发挥作用。
- 其他临床常用阿片类药物的药物基因组学实施指南目前仍缺乏。
研究设计与样本
- 本文为综述,汇总了多项药物代谢动力学研究及药物基因组学证据。
主要发现
- 多项药代动力学研究显示,代谢酶基因多态性可导致阿片类药物暴露和/或代谢存在显著差异。
- 部分研究中,药物暴露差异转化为阿片相关不良反应发生率的差异,尤其恶心、呕吐、便秘和呼吸抑制。
- OPRM1和COMT多态性与阿片疗效的关联研究结果存在矛盾,部分证据提示OPRM1可能相关。
关键数值与推荐
- CPIC指南基于CYP2D6基因型提供可待因和曲马多的治疗推荐。
- 其他常用阿片类药物目前缺乏实施指南。
临床怎么用
- 对使用可待因或曲马多的患者,可参考CPIC的CYP2D6基因型指导治疗推荐进行个体化决策。
- 使用其他阿片类药物时,药物基因组学证据尚不足以常规指导临床,需结合临床评估。
局限性
- 关于OPRM1和COMT多态性与阿片疗效的关联,现有研究结果不一致。
- 其他常用阿片类药物缺乏药物基因组学实施指南,证据基础有待补充。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Opioid analgesics are the standards of care for the treatment of moderate to severe nociceptive pain, particularly in the setting of cancer and surgery. Their analgesic properties mainly emanate from stimulation of the μ receptors, which are encoded by the OPRM1 gene. Hepatic metabolism represents the major route of elimination, which, for some opioids, namely codeine and tramadol, is necessary for their bioactivation into more potent analgesics. The highly polymorphic nature of the genes coding for phase I and phase II enzymes (pharmacokinetics genes) that are involved in the metabolism and bioactivation of opioids suggests a potential interindividual variation in their disposition and, most likely, response. In fact, such an association has been substantiated in several pharmacokinetic studies described in this review, in which drug exposure and/or metabolism differed significantly based on the presence of polymorphisms in these pharmacokinetics genes. Furthermore, in some studies, the observed variability in drug exposure translated into differences in the incidence of opioid-related adverse effects, particularly nausea, vomiting, constipation, and respiratory depression. Although the influence of polymorphisms in pharmacokinetics genes, as well as pharmacodynamics genes (OPRM1 and COMT) on response to opioids has been a subject of intense research, the results have been somehow conflicting, with some evidence insinuating for a potential role for OPRM1. The Clinical Pharmacogenetics Implementation Consortium guidelines provide CYP2D6-guided therapeutic recommendations to individualize treatment with tramadol and codeine. However, implementation guidelines for other opioids, which are more commonly used in real-world settings for pain management, are currently lacking. Hence, further studies are warranted to bridge this gap in our knowledge base and ultimately ascertain the role of pharmacogenetic markers as predictors of response to opioid analgesics.
引用
- Owusu Obeng A, Hamadeh I, Smith M, et al. Review of Opioid Pharmacogenetics and Considerations for Pain Management. Pharmacotherapy. 2017. PMID: 28699646. doi:10.1002/phar.1986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。